Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients
Identifieur interne : 002368 ( Main/Exploration ); précédent : 002367; suivant : 002369Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients
Auteurs : Yonghong Zhang [République populaire de Chine] ; Yali Liu [République populaire de Chine] ; Yan Zhao [République populaire de Chine] ; Lingxian Shi [République populaire de Chine] ; Lina Ma [République populaire de Chine] ; Huiping Yan [République populaire de Chine] ; Hao Wu [République populaire de Chine] ; Lai Wei [République populaire de Chine] ; Tao Dong [Royaume-Uni] ; Xinyue Chen [République populaire de Chine]Source :
- Liver International [ 1478-3223 ] ; 2012-01.
English descriptors
- Teeft :
- Acute hepatitis, Antiviral therapy, Assay, Baseline, Beijing, Beijing youan hospital, Cell responses, Certain patients, Chronic hepatitis, Chronic infection, Chronic patients, Clin virol, Combination therapy, Combination treatment, Control wells, Demographic characteristics, Early virological response, Elispot, Elispot assay, Genetic variation, Genotype, Hepatitis, Interferon, John wiley sons, John wiley sons response, John wiley sons zhang, Nonstructural, Nonstructural protein, Ns5a, Pbmcs, Peptide, Peptide pools, Peripheral blood, Rapid virological response, Responsive patients, Ribavirin, Study group, Suppressive effect, Therapy, Undetectable serum, Viral, Viral clearance, Viral kinetics, Viral load, Virological, Virological response, Virus clearance, Virus infection, Virus nonstructural protein, Zhang.
Abstract
Background: Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (HCV)‐specific T‐cell responses on combination therapy still remains controversial. Aims: To identify the association between HCV‐specific T cell responses and efficiency of combination therapy. Methods: To address this issue, a longitudinal analysis of HCV‐specific T‐cell responses to overlapping peptides covering HCV‐nonstructural protein (NS) was performed using ELISpot assay in 48 chronically infected HCV‐1b patients during combination treatment with peginterferon‐alfa and ribavirin. Results: Fifty‐two percent of chronic HCV patients showed detectable HCV‐NS3, NS4 or NS5A specific T‐cell responses before therapy, with NS3 appearing to be the most immunodominant protein followed by NS5A and NS4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (SVR) when compared with those without SVR. Dynamics of HCV‐NS‐specific T‐cell responses were further analysed; we found that HCV‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with SVR. In contrast, HCV‐specific T‐cell responses in patients without SVR declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks. Conclusion: We found that the HCV‐specific T‐cell responses were associated with good viral control in patients with combination therapy.
Url:
DOI: 10.1111/j.1478-3231.2011.02652.x
Affiliations:
- Royaume-Uni, République populaire de Chine
- Angleterre, Oxfordshire
- Oxford, Pékin
- Université d'Oxford
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001392
- to stream Istex, to step Curation: 001392
- to stream Istex, to step Checkpoint: 000385
- to stream Main, to step Merge: 002393
- to stream Main, to step Curation: 002368
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title><author><name sortKey="Zhang, Yonghong" sort="Zhang, Yonghong" uniqKey="Zhang Y" first="Yonghong" last="Zhang">Yonghong Zhang</name></author><author><name sortKey="Liu, Yali" sort="Liu, Yali" uniqKey="Liu Y" first="Yali" last="Liu">Yali Liu</name></author><author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name></author><author><name sortKey="Shi, Lingxian" sort="Shi, Lingxian" uniqKey="Shi L" first="Lingxian" last="Shi">Lingxian Shi</name></author><author><name sortKey="Ma, Lina" sort="Ma, Lina" uniqKey="Ma L" first="Lina" last="Ma">Lina Ma</name></author><author><name sortKey="Yan, Huiping" sort="Yan, Huiping" uniqKey="Yan H" first="Huiping" last="Yan">Huiping Yan</name></author><author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name></author><author><name sortKey="Wei, Lai" sort="Wei, Lai" uniqKey="Wei L" first="Lai" last="Wei">Lai Wei</name></author><author><name sortKey="Dong, Tao" sort="Dong, Tao" uniqKey="Dong T" first="Tao" last="Dong">Tao Dong</name></author><author><name sortKey="Chen, Xinyue" sort="Chen, Xinyue" uniqKey="Chen X" first="Xinyue" last="Chen">Xinyue Chen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1478-3231.2011.02652.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001392</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001392</idno><idno type="wicri:Area/Istex/Curation">001392</idno><idno type="wicri:Area/Istex/Checkpoint">000385</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000385</idno><idno type="wicri:doubleKey">1478-3223:2012:Zhang Y:hepatitis:c:virus</idno><idno type="wicri:Area/Main/Merge">002393</idno><idno type="wicri:Area/Main/Curation">002368</idno><idno type="wicri:Area/Main/Exploration">002368</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title><author><name sortKey="Zhang, Yonghong" sort="Zhang, Yonghong" uniqKey="Zhang Y" first="Yonghong" last="Zhang">Yonghong Zhang</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Liu, Yali" sort="Liu, Yali" uniqKey="Liu Y" first="Yali" last="Liu">Yali Liu</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Shi, Lingxian" sort="Shi, Lingxian" uniqKey="Shi L" first="Lingxian" last="Shi">Lingxian Shi</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Ma, Lina" sort="Ma, Lina" uniqKey="Ma L" first="Lina" last="Ma">Lina Ma</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Yan, Huiping" sort="Yan, Huiping" uniqKey="Yan H" first="Huiping" last="Yan">Huiping Yan</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wei, Lai" sort="Wei, Lai" uniqKey="Wei L" first="Lai" last="Wei">Lai Wei</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Peking University Hepatology Institute, Peking University People's Hospital, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Dong, Tao" sort="Dong, Tao" uniqKey="Dong T" first="Tao" last="Dong">Tao Dong</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Human Immunolgy Unit, WIMM, University of Oxford, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Chen, Xinyue" sort="Chen, Xinyue" uniqKey="Chen X" first="Xinyue" last="Chen">Xinyue Chen</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing You'an Hospital, Capital Medical University,, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">République populaire de Chine</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Liver International</title><title level="j" type="alt">LIVER INTERNATIONAL</title><idno type="ISSN">1478-3223</idno><idno type="eISSN">1478-3231</idno><imprint><biblScope unit="vol">32</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="102">102</biblScope><biblScope unit="page" to="109">109</biblScope><biblScope unit="page-count">8</biblScope><date type="published" when="2012-01">2012-01</date></imprint><idno type="ISSN">1478-3223</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1478-3223</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute hepatitis</term><term>Antiviral therapy</term><term>Assay</term><term>Baseline</term><term>Beijing</term><term>Beijing youan hospital</term><term>Cell responses</term><term>Certain patients</term><term>Chronic hepatitis</term><term>Chronic infection</term><term>Chronic patients</term><term>Clin virol</term><term>Combination therapy</term><term>Combination treatment</term><term>Control wells</term><term>Demographic characteristics</term><term>Early virological response</term><term>Elispot</term><term>Elispot assay</term><term>Genetic variation</term><term>Genotype</term><term>Hepatitis</term><term>Interferon</term><term>John wiley sons</term><term>John wiley sons response</term><term>John wiley sons zhang</term><term>Nonstructural</term><term>Nonstructural protein</term><term>Ns5a</term><term>Pbmcs</term><term>Peptide</term><term>Peptide pools</term><term>Peripheral blood</term><term>Rapid virological response</term><term>Responsive patients</term><term>Ribavirin</term><term>Study group</term><term>Suppressive effect</term><term>Therapy</term><term>Undetectable serum</term><term>Viral</term><term>Viral clearance</term><term>Viral kinetics</term><term>Viral load</term><term>Virological</term><term>Virological response</term><term>Virus clearance</term><term>Virus infection</term><term>Virus nonstructural protein</term><term>Zhang</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (HCV)‐specific T‐cell responses on combination therapy still remains controversial. Aims: To identify the association between HCV‐specific T cell responses and efficiency of combination therapy. Methods: To address this issue, a longitudinal analysis of HCV‐specific T‐cell responses to overlapping peptides covering HCV‐nonstructural protein (NS) was performed using ELISpot assay in 48 chronically infected HCV‐1b patients during combination treatment with peginterferon‐alfa and ribavirin. Results: Fifty‐two percent of chronic HCV patients showed detectable HCV‐NS3, NS4 or NS5A specific T‐cell responses before therapy, with NS3 appearing to be the most immunodominant protein followed by NS5A and NS4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (SVR) when compared with those without SVR. Dynamics of HCV‐NS‐specific T‐cell responses were further analysed; we found that HCV‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with SVR. In contrast, HCV‐specific T‐cell responses in patients without SVR declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks. Conclusion: We found that the HCV‐specific T‐cell responses were associated with good viral control in patients with combination therapy.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>République populaire de Chine</li></country><region><li>Angleterre</li><li>Oxfordshire</li></region><settlement><li>Oxford</li><li>Pékin</li></settlement><orgName><li>Université d'Oxford</li></orgName></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Zhang, Yonghong" sort="Zhang, Yonghong" uniqKey="Zhang Y" first="Yonghong" last="Zhang">Yonghong Zhang</name></noRegion><name sortKey="Chen, Xinyue" sort="Chen, Xinyue" uniqKey="Chen X" first="Xinyue" last="Chen">Xinyue Chen</name><name sortKey="Chen, Xinyue" sort="Chen, Xinyue" uniqKey="Chen X" first="Xinyue" last="Chen">Xinyue Chen</name><name sortKey="Liu, Yali" sort="Liu, Yali" uniqKey="Liu Y" first="Yali" last="Liu">Yali Liu</name><name sortKey="Ma, Lina" sort="Ma, Lina" uniqKey="Ma L" first="Lina" last="Ma">Lina Ma</name><name sortKey="Shi, Lingxian" sort="Shi, Lingxian" uniqKey="Shi L" first="Lingxian" last="Shi">Lingxian Shi</name><name sortKey="Wei, Lai" sort="Wei, Lai" uniqKey="Wei L" first="Lai" last="Wei">Lai Wei</name><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name><name sortKey="Yan, Huiping" sort="Yan, Huiping" uniqKey="Yan H" first="Huiping" last="Yan">Huiping Yan</name><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dong, Tao" sort="Dong, Tao" uniqKey="Dong T" first="Tao" last="Dong">Tao Dong</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002368 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002368 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D
|texte= Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients
}}
| This area was generated with Dilib version V0.6.33. |  |